Phase II study combining gefitinib with etoposide in patients with hormone-refractory metastatic prostate cancer (mHRPC) after docetaxel-based therapy.

Ralph J. Hauke,F R Loberiza,J. E. Elkahwaji,P. M. Townley,G. K. Bascom,Ming Fong Lin,S Batra

Phase II study combining gefitinib with etoposide in patients with hormone-refractory metastatic prostate cancer (mHRPC) after docetaxel-based therapy.

2010

Ralph J. Hauke
F R Loberiza
J. E. Elkahwaji
P. M. Townley
G. K. Bascom
Ming Fong Lin
S Batra

e15071 Background: Second-line chemotherapy after docetaxel-based regimens for mHRPC remains undefined. Epithelial growth factor receptor (EGFR) expression is increased in prostate cancer. Clinical...

Keywords:

Hormone
Etoposide
Physical therapy
Phases of clinical research
Cancer research
Prostate cancer
Oncology
Gefitinib
Internal medicine
Medicine
Docetaxel
Growth factor receptor
in patient
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations